Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Deferasirox in Low Risk MDS
NCT01058369Phase 2Terminated
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Apr 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Fraction of Patients With Hematologic Improvement According to Modified IWG Criteria at 2 years. Started Apr 2010; status: terminated.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01058369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058369.